Canagliflozin Increases Postprandial Total Glucagon-Like Peptide-1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-Randomized, Open-Label Study.

Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides</p

Time-change profile of plasma liraglutide concentration following subcutaneous administration of liraglutide in diabetic patients with ESRD on the days of on-hemodialysis and off-hemodialysis.

<p>n = 10.</p><p>Time-change profile of plasma liraglutide concentration following subcutaneous administration of liraglutide in diabetic patients with ESRD on the days of on-hemodialysis and off-hemodialysis.</p

Baseline demographics and characteristics of the patients.

<p>*Values are mean ± SD (n = 10).</p><p>**0.9 mg (8 males and 1 female), 0.6 mg (1 male).</p><p>***1 patient had previously been treated with insulin only, and had switched to liraglutide 3 months prior to initiation of the study.</p><p>AST: Aspartate aminotransferase (SGOT).</p><p>ALT: Alanine aminotransferase (SGPT).</p><p>BUN: Blood urea nitrogen.</p><p>CPK: Creatinine phosphokinase.</p><p>Baseline demographics and characteristics of the patients.</p

Patient disposition.

<p>Patient disposition.</p

Patient disposition.

<p>Patient disposition.</p

Pharmacokinetic parameters of liraglutide following subcutaneous administration of liraglutide to diabetic patients with ESRD on the day of on-hemodialysis and off-hemodialysis.

<p>-: not calculated, n = 10.</p><p>Pharmacokinetic parameters of liraglutide following subcutaneous administration of liraglutide to diabetic patients with ESRD on the day of on-hemodialysis and off-hemodialysis.</p

Plasma glucose profiles after subcutaneous administration of liraglutide in diabetic patients with ESRD on-hemodialysis and off-hemodialysis.

<p>Mean ± SD, n = 10.</p><p>*The analysis of 95% CI (log [CI]) could not be performed because zero values were included.</p><p>**p<0.05.</p><p>Plasma glucose profiles after subcutaneous administration of liraglutide in diabetic patients with ESRD on-hemodialysis and off-hemodialysis.</p

Multivariate regression analysis adjusted for age, gender and BMI.

Multivariate regression analysis adjusted for age, gender and BMI.</p

Characteristics according to quintile categories of type 1 life style pattern score.

<p>Characteristics according to quintile categories of type 1 life style pattern score.</p

Life style items and factor analysis with oblique promax rotation.

<p>Life style items and factor analysis with oblique promax rotation.</p